Novel composition for nonalcoholic fatty liver disease (nafld)

Abstract

The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein ‘R’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).

1 - 26 . (canceled) 
     
     
         27 . A method of ameliorating fibrosis, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable salt of 
       
         
           
           
               
               
           
         
       
       wherein R is —S-methyl, 
       to ameliorate the fibrosis. 
     
     
         28 . The method of  claim 27 , wherein the pharmaceutically acceptable salt is a metal cation salt. 
     
     
         29 . The method of  claim 27 , wherein the pharmaceutically acceptable salt is a metal cation salt selected from the group consisting of a sodium salt, potassium salt, calcium salt, and magnesium salt. 
     
     
         30 . The method of  claim 27 , wherein the pharmaceutically acceptable salt is a magnesium salt. 
     
     
         31 . A method of ameliorating fibrosis, comprising administering to a subject in need thereof a therapeutically effective amount of 
       
         
           
           
               
               
           
         
       
       wherein R is —S-methyl, and M +  is a metal cation, to ameliorate the fibrosis. 
     
     
         32 . The method of  claim 31 , wherein M +  is Mg 2+ . 
     
     
         33 . A method of treating cirrhosis, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable salt of 
       
         
           
           
               
               
           
         
       
       wherein R is —S-methyl, 
       to treat the cirrhosis. 
     
     
         34 . The method of  claim 33 , wherein the pharmaceutically acceptable salt is a metal cation salt. 
     
     
         35 . The method of  claim 33 , wherein the pharmaceutically acceptable salt is a metal cation salt selected from the group consisting of a sodium salt, potassium salt, calcium salt, and magnesium salt. 
     
     
         36 . The method of  claim 33 , wherein the pharmaceutically acceptable salt is a magnesium salt. 
     
     
         37 . A method of treating cirrhosis, comprising administering to a subject in need thereof a therapeutically effective amount of 
       
         
           
           
               
               
           
         
       
       wherein R is —S-methyl, and M +  is a metal cation, to treat the cirrhosis. 
     
     
         38 . The method of  claim 37 , wherein M +  is Mg 2+ .